Search results
Results from the WOW.Com Content Network
For many biologics (e.g., monoclonal antibodies), injection site reactions are the most common adverse effect of the drug, and have been reported to have an incidence rate of 0.5–40%. [2] In trials of subcutaneous administration of oligonucleotides, between 22 and 100% of subjects developed reactions depending on the oligonucleotide. [6]
Phenformin is an antidiabetic drug from the biguanide class. It was marketed as DBI by Ciba-Geigy, but was withdrawn from most markets in the late 1970s due to a high risk of lactic acidosis, which was fatal in 50% of cases.
Type IV hypersensitivity, in the Gell and Coombs classification of allergic reactions, often called delayed-type hypersensitivity, is a type of hypersensitivity reaction that can take a day or more to develop. [1] Unlike the other types, it is not humoral (not antibody-mediated) but rather is a type of cell-mediated response.
There are different classes of hypoglycemic drugs, and selection of the appropriate agent depends on the nature of diabetes, age, and situation of the person, as well as other patient factors. Type 1 diabetes is a disease caused by the lack of insulin. Thus, insulin is the main treatment agent for type 1 and is typically administered via ...
People have had severe infusion-related reactions to pembrolizumab. There have also been severe immune-related adverse effects including lung inflammation (including fatal cases) and inflammation of endocrine organs that caused inflammation of the pituitary gland, of the thyroid (causing both hypothyroidism and hyperthyroidism in different people), and pancreatitis that caused Type 1 diabetes ...
It can cause a physical reaction that may present differently depending on the person, but symptoms often mirror skin conditions like eczema, hives, or other allergic reactions.
Pioglitazone, sold under the brand name Actos among others, is an anti-diabetic medication used to treat type 2 diabetes. [3] It may be used with metformin, a sulfonylurea, or insulin. [3] [4] Use is recommended together with exercise and diet. [4] It is not recommended in type 1 diabetes. [4] It is taken by mouth. [4]
The combination was refused approval by the US Food and Drug Administration (FDA) in 2023. [11] It was approved for medical use in Canada in May 2023, [ 4 ] in Australia in March 2024, [ 1 ] and in the United States in October 2024.